FDA Expands Approval of Ceritinib for ALK-Positive Non-Small Cell Lung Cancer



The FDA has approved the targeted therapy ceritinib as an initial treatment for patients with lung cancer that has a mutation in the ALK gene.



Source link

Comments are closed.